Table 10.
Outcomes and toxicity of alloSCT after exposure to checkpoint inhibitors.
| Characteristics/Outcomes/Toxicities | Merryman et al. [142] | Armand et al. (Checkmate 205) [124] |
|---|---|---|
| Patients (number) | 31 | 44 |
| Time from last PD1 dose to alloSCT (days; median (range)) | 62 (7–260) * | 49 (IQR 31–127) |
| Salvage between PD1 and alloSCT (%) | 49 * | 27 |
| Hyperacute GvHD (within 14 days) (%) | NR | 11 |
| Cumulative Incidence of aGvHD (grade 2–4) at 6 mo/1 yr | NR/45 | 30/45 ** |
| Cumulative Incidence of aGvHD (grade 3–4) at 6 mo/1 yr | NR/26 | 20/32 ** |
| Cumulative Incidence of cGvHD at 6 mo/1 yr | NR/33 | 15/20 ** |
| Liver Sinusoidal Obstructive Syndrome | 6% at 3 months | 2% |
| Non-infectious Febrile Syndrome (%) | 18 * | 9 |
| Other Toxicities | - | Encephalitis 2% |
| Treatment-Related Deaths (number, %) | 3 (10%) | 5 (11%) |
| Cumulative Incidence of Non Relapse Mortality at 6 mo/1 yr (%) | NR/10 | 13/13 ** |
| Cumulative Incidence of Relapse at 6 mo/1 yr (%) | NR/16 | 7/13 |
| Progression Free Survival at 6 mo/1 yr (%) | NR/74 | 82/77 |
| Overall Survival at 6 mo/1 yr (%) | NR/90 | 87/79 |
aGvHD = acute graft versus host disease; NR = not reported. * among the total of 39 patients included in the study (8 with non-Hodgkin’s lymphomas); ** one-year rates approximated from the published survival curves.